【摘要】 心力衰竭是各种心脏疾病的终末阶段，其发生发展涉及复杂的病理生理过程，其中心肌代谢异常是不可忽视的因素之一。钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂作为一种新型口服降糖药，在降低心血管疾病的死亡率和心力衰竭患者的再住院率，调节心脏代谢方面发挥了显著作用。本综述阐述正常及衰竭心脏的代谢变化，并对SGLT2抑制剂对心力衰竭中心肌代谢方面的影响进行总结，旨在指导临床用药。更多还原

【Abstract】 Heart failure is the end stage of various heart diseases. Its occurrence and development involve complex pathophysiological process, among which abnormal myocardial metabolism is one of the factors that cannot be ignored. Sodium-glucose cotransporter 2 inhibitors(SGLT2i), as a novel oral hypoglycemic agent, plays a significant role in reducing the mortality of cardiovascular diseases and the rehospitalization rate of patients with heart failure, and regulating cardiac metabolism. The present review elaborates the metabolic changes of normal and failing hearts, and summarizes the effects of SGLT2i on myocardial metabolism in heart failure, aiming to guide clinical medication.更多还原